Independent Conference Coverage: Expert Analyses of Atopic Dermatitis Research Results and Their Potential Impact on Patient Care*

Skin pain is a separate and highly bothersome symptom for children with AD.

Study suggests that treatment with abrocitinib 200 mg QD results in a greater and more rapid response vs dupilumab, as assessed using stringent endpoints.

Rapid, clinically meaningful, and continual improvement in itch observed with ruxolitinib cream for patients with atopic dermatitis.

Case series suggests efficacy of itraconazole for the treatment of dupilumab facial redness.